NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
Recruiting
Phase 2
Interventional Study
Major Depressive Disorder
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 50 (estimated)
- Sponsor
- China Medical University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of antidepressant nonresponders with MDD.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Have a DSM-5 (American Psychiatric Association) diagnosis of MDD
* Have failed to respond to at least one antidepressant with adequate dosage and treatment duration
* Their original treatments should have been unchanged for at least 8 weeks. Some treatment-resistant patients (…
Contacts